Cite
Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression
MLA
Purwanto I, et al. “Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and P53 Mutant Expression.” Breast Cancer: Targets and Therapy, vol. ume 15, July 2023, pp. 515–24. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1f039e859914298bfd438916467cfd3&authtype=sso&custid=ns315887.
APA
Purwanto I, Leo B, Hutajulu SH, Kurnianda J, Taroeno-Hariadi KW, Hardianti MS, Satiti AD, Dwianingsih EK, Heriyanto DS, Widodo I, & Aryandono T. (2023). Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression. Breast Cancer: Targets and Therapy, ume 15, 515–524.
Chicago
Purwanto I, Leo B, Hutajulu SH, Kurnianda J, Taroeno-Hariadi KW, Hardianti MS, Satiti AD, et al. 2023. “Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and P53 Mutant Expression.” Breast Cancer: Targets and Therapy ume 15 (July): 515–24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1f039e859914298bfd438916467cfd3&authtype=sso&custid=ns315887.